PAK4 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL20937	0.71	11/20
SCHEMBL24667	0.75	10/20
SCHEMBL25738	0.77	9/20
SCHEMBL98881	0.57	3/20
SCHEMBL100736	0.50	3/20
SCHEMBL100040	0.48	3/20
SCHEMBL100903	0.47	3/20
SCHEMBL101889	0.46	3/20
SCHEMBL101518	0.45	3/20
SCHEMBL99210	0.43	3/20
SCHEMBL101240	0.41	3/20
Staurosporine (SCHEMBL8156)	1.00	2/20
Staurosporine (SCHEMBL8157)	1.00	2/20
Ruxolitinib (SCHEMBL99225)	1.00	2/20
Ruxolitinib (SCHEMBL101279)	1.00	2/20
SCHEMBL99245	0.98	2/20
SCHEMBL99371	0.98	2/20
SCHEMBL103135	0.98	2/20
SCHEMBL98692	0.92	2/20
Ruxolitinib (SCHEMBL99771)	0.84	2/20

Clinical trials — most relevant to PAK4 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus	PHASE2	COMPLETED
Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer	PHASE1/PHASE2	COMPLETED
Perifosine in Treating Patients With Recurrent, Refractory, Locally Advanced, or Metastatic Breast Cancer	PHASE2	COMPLETED
A Phase II Study of EVEROLIMUS in Patients With Primary or Relapsed Chondrosarcomas	PHASE2	SUSPENDED
Hydroxychloroquine to Increase Tumor Suppressor PAR-4 Levels in Oligometastatic Prostate Cancer	PHASE2	COMPLETED
Study of Sorafenib and Docetaxel in Metastatic Prostate Cancer	PHASE2	COMPLETED
Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery	PHASE2	COMPLETED
The Controlled Trial of Apremilast for Rheumatoid Arthritis Treatment (CARAT)	PHASE2	COMPLETED
Selective Treatment According to Molecular Subtype of Prostate Cancer	PHASE2	UNKNOWN
Selumetinib in Treating Patients With Biliary Cancer That Cannot Be Removed By Surgery	PHASE2	COMPLETED
STAR Cape+BKM120 MBC With Brain Met	PHASE2	COMPLETED
A Study of GSK2256098 and Trametinib in Advanced Pancreatic Cancer	PHASE2	COMPLETED
KPT-9274 in Patients With Relapsed and Refractory Acute Myeloid Leukemia	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers	PHASE1	COMPLETED
Pre-Surgical Trial of the Combination of Metformin and Atorvastatin in Newly Diagnosed Operable Breast Cancer	EARLY_PHASE1	COMPLETED
Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212	EARLY_PHASE1	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
The Phosphodiesterase-3 Inhibitor Cilostazol as an Adjunctive to Antidepressants in Patients With Major Depressive Disorder.	nan	COMPLETED
Rostock International Parkinson's Disease Study (ROPAD)	nan	COMPLETED
Molecular Phenotype Changes and Personalized Treatment for CRPC	nan	UNKNOWN
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
Evaluation the Topical Apremilast Nanoformulation in Treatment of Localized Plaque Psoriasis	nan	NOT_YET_RECRUITING
Molecular Analysis of Thoracic Malignancies	nan	ENROLLING_BY_INVITATION
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Biomarker Analysis of Gastrointestinal Cancer	nan	UNKNOWN
Acceptance and Commitment Therapy for Caregivers of Children With a RASopathy: An Internal Pilot Feasibility Study and Follow-up Randomized Controlled Trial	nan	RECRUITING
Association Between Intakes of Protein, Calcium and Milk With Gene Expression and Linear Growth of School Aged Children	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PAK4 binder may also engage these)

Protein	Name	Similarity
Q8BTW9	—	1.000	Q8BTW9 →
Q3ULB5	—	0.997	Q3ULB5 →
Q5R8Z4	—	0.997	Q5R8Z4 →
PAK6	Serine/threonine-protein kinase PAK 6	0.995	landscape →
MAPK7	Mitogen-activated protein kinase 7	0.993	landscape →
Q8CIP4	—	0.992	Q8CIP4 →
Q0PKV7	—	0.991	Q0PKV7 →
MKNK1	MAP kinase-interacting serine/threonine-protein kinase 1	0.991	landscape →
A5PKJ4	—	0.990	A5PKJ4 →
Q9TUI4	—	0.990	Q9TUI4 →
Q9CAU7	—	0.990	Q9CAU7 →
Q8RXT4	—	0.990	Q8RXT4 →
Q0DCT8	—	0.990	Q0DCT8 →
Q2QMH1	—	0.990	Q2QMH1 →
Q96P47	—	0.989	Q96P47 →
Q63553	—	0.989	Q63553 →
Q17QV9	—	0.989	Q17QV9 →
A3KMV1	—	0.989	A3KMV1 →
Q05512	—	0.989	Q05512 →
Q8JZP2	—	0.989	Q8JZP2 →
O70441	—	0.989	O70441 →
MAP4K4	Mitogen-activated protein kinase kinase kinase kinase 4	0.989	landscape →
Q7TNL3	—	0.989	Q7TNL3 →
Q8RX66	—	0.989	Q8RX66 →
O88808	—	0.989	O88808 →
MARK2	Serine/threonine-protein kinase MARK2	0.989	landscape →
Q501Q9	—	0.989	Q501Q9 →
Q7RZD3	—	0.989	Q7RZD3 →
B9EHT4	—	0.989	B9EHT4 →
Q9JM52	—	0.989	Q9JM52 →